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Introduction
The prevalence of benzodiazepine (BZD) and related drug (Z drug) use, that is benzodiazepine and related drug (BZDR) use, among older people varies between 9-32% in developed countries (1) (2) (3) (4) (5) . Their adverse effects and events include drowsiness, higher risk of falls and hip fractures and mobility problems (6) . Despite the recommendations (7), BZDRs are commonly used long term (8) . Short-term negative effects on memory and cognition are well known (9-12.) Thus, their longterm use has been hypothesized to hasten cognitive decline and increase dementia risk.
Alzheimer's disease (AD) accounts for 60-80% of dementia cases (13) . BZDRs are used to treat prodromal or neuropsychiatric symptoms of dementia/AD such as anxiety and insomnia (14) (15) (16) . Because AD has long latency period, prodromal symptoms can arise years before diagnosis of AD. Thus, protopathic bias must be taken into account using sufficient time lag between BZDR use and AD. In most of the studies, the time lag in main analyses has been 1-2 years (17) (18) (19) (20) , and in one study 5 years (21) . These studies have been inconsistent, with some claiming that BZDRs and BZDs are AD/dementia risk factors (18, 21, 22) and others reporting no association (20) . One, without any time lag reported that BZDs were associated with decreased risk of AD (23) . A recent meta-analysis (22) concluded about 50% increased dementia risk among BZDRs users.
Studies on dose-response relationship of BZDs have been equally heterogeneous, with two studies showing a dose-response effect (18, 21) , one reporting an increased risk with smaller cumulative doses only (17) , and one reporting null results (20) . We are aware on only one study that assessed association between Z drugs and AD or vascular dementia, concluding with null results (20) .
The impact of elimination time has also been debated. Three previous studies found higher dementia risk for those who used long-acting BZDRs compared to those who used short-acting BZDRs (18, 19, 21) . One study (19) found the risk only for long-acting but not for short-acting BZDRs and one study (20) found no associations.
Aims of the study
We assessed the association between benzodiazepine and related drug use and risk of Alzheimer's disease in a nationwide nested case-control study of all clinically verified Alzheimer's disease cases diagnosed in Finland in [2005] [2006] [2007] [2008] [2009] [2010] [2011] . The effect of dose, half-life, cumulative consumption and duration, as well as the individual associations of benzodiazepines and Z drugs, were examined.
Material and methods

Study population
Cases of the study were from the nationwide MEDALZ (Medication use and Alzheimer's disease) cohort that includes all Finnish communitydwelling persons who received a clinically verified AD diagnosis in 2005-2011 (N = 70 719, age range 34-105 years, 65.2% women) (24) . To conduct a nested case-control study of the population of Finland, 1-4 age, sex and region of residence matched controls were identified for each case (N = 282 862).
Data sources
Data were extracted from the Special Reimbursement Register (since 1972), the Prescription Register (since 1995), the Hospital Discharge Register (since 1972) and the population censuses maintained by Statistics Finland since 1970. All data sources have nationwide coverage.
Register data were retrieved using personal identity numbers (25) . All data were de-identified before submission to the research team, and therefore, ethics committee approval was not required according to Finnish legislation. Permissions for data use were received from register maintainers. Registers and linkage process have been previously described in detail (24) .
Identification of AD cases
The AD cases were identified from the Special Reimbursement Register. The diagnostic criteria of AD were based on NINCDS-ADRDA (26) and DSM-IV (27) . All AD cases had to fulfil the requirements for the reimbursement of anti-AD drugs which are as follows: (i) symptoms consistent with AD; (ii) a decrease in social capacity over a period of at least 3 months; (iii) received a computed tomography/magnetic resonance imaging scan; (iv) had possible alternative diagnoses excluded; and (v) received confirmation of the diagnosis by a registered neurologist or geriatrician (28) .
Identification of controls
The matched controls were identified from nationwide registers of the Social Insurance Institution of Finland (SII) including all residents with the following criteria: (i) alive and community-dwelling during the last day of the month when case was diagnosed with AD (index date); (ii) no special reimbursement for AD medication or acetylcholinesterase inhibitor or memantine purchases (N06D) before index date and within 12 months after it.
BZDR use
Benzodiazepine and related drugs are categorized according to World Health Organization's Anatomical Therapeutic Chemical (ATC) classification system (29) . BZDRs were defined as benzodiazepines (ATC-classes N05BA and N05CD and clonazepam N03AE01) and benzodiazepinerelated drugs, so called Z drugs (ATC class N05CF). Various combination products including a BZD component, such as combination of diazepam with glycopyrronium, were identified as being on market and used by the study cohort during the follow-up, and these also were included in analysis. Use of combination products was recoded to the use of the corresponding BZD substance (diazepam-glycopyrronium recoded as diazepam use) to retrieve total duration of use and cumulative consumption for each drug substance (Table S1 ).
Benzodiazepine and related drugs were classified into short-/medium-and long-acting BZDRs according to Gomm et al. (18) , with the exception of alprazolam that was classified as long-acting, because of its increased half-life in old adults (30 Benzodiazepine and related drug use was calculated since 1995 until 5 years before the index date (date of AD diagnosis of the index case). BZDR use was defined as any BZDR use during the follow-up.
Benzodiazepine and related drug use periods, that is when continuous drug use started and ended, were calculated using validated PRE2DUP-method from prescription register data (31, 32) . The method is based on mathematical modelling and calculation of sliding averages of Defined Daily Dose (DDD) (33) for each ATC code. Each drug substance was modelled separately and then overlapping use periods combined to retrieve 'any BZDR use'. Individuals could change the BZDR substance during the 'any BZDR' use period. BZD, Z drug, long-acting and short-/medium-acting BZDR use periods were constructed similarly.
To study the impact of exposure duration, BZDR use was categorized into four groups according to the cumulative duration of BZDR use: 1 day-1 month, 1 month-1 year, 1-5 years and over 5 years. Same cut-offs were used for BZDs, Z drugs, short-/medium-acting BZDRs and long-acting BZDRs.
To study the effect of cumulative BZDR consumption in DDDs, cumulative amount of DDDs were calculated from drug purchase data. Cumulative sum of DDDs was categorized to three groups according to tertiles of cumulative consumption: For dose-dependency analyses, cumulative purchased amount in DDDs was divided by duration of use for each person to define the average BZDR dose. The average BZDR dose was categorized to low (>0 to <0.5 DDD/day), medium (≥0.5 to <1 DDD/day) and high (≥1 DDD/day). Doses were categorized similarly for BZDs and Z drugs.
Confounders
The following comorbidities were used for adjustment: asthma/COPD, any cardiovascular disease (arrhythmia, hypertension, coronary disease or heart failure) and diabetes from the Special Reimbursement Register and mental and behavioural disorders (any of ICD-10 F-codes, excluding F00-F03 dementia diagnoses, and corresponding ICD-9 and -8 codes) from the Hospital Discharge register from 1972 onwards.
A composition variable indicating substance abuse was derived from the Hospital Discharge Register data using mental and behavioural disorders due to psychoactive substance use (ICD-10 codes F10-F19), alcohol-induced chronic pancreatitis (ICD-10 codes K86.00, K86.01 and K86.08) and hospitalizations due to substance abuse.
Antipsychotic use (purchased or not antipsychotics class N05A excluding lithium (N05AN)) and similarly antidepressant use (all antidepressants (N06A) excluding 'Monoamine oxidase inhibitors, non-selective' (N06AF) as they were not on market in Finland during the study period) was extracted from the Prescription register since 1995.
Socioeconomic position, defined as the highest occupational social class, was obtained from the censuses maintained by Statistics Finland. The data were collected on 5-year intervals between 1970 and 1990, on 1993, 1995, 2000, and annually from 2004 onwards. An ordinal variable with the following categories was derived 'managerial/professional', 'office worker', 'farming/forestry', 'sales/industry/cleaning', 'unknown' and 'did not respond'.
All confounders were extracted until 5 years before the AD diagnosis of the index case.
Statistical analysis
All analyses were conducted using Stata, version 13.1. All continuous variables were compared with Wilcoxon rank-sum test due to skewed distributions. All categorical variables were compared with conditional logistic regression.
The associations between BZDR exposure and AD were assessed with conditional logistic regression. To account for reverse causality, only drug use that occurred at least 5 years before AD diagnosis was considered in the analysis. Those persons who were exposed only during the lag time were not included in the analyses. Persons who did not use any BZDRs during follow-up (1995-2011) were used as reference group (N = 190 924). Similar 5-year time lag was applied to confounders. To calculate the attributable proportion among the exposed (i.e. the proportion of disease in the exposed group that can be attributed to the exposure), the following formula was used:
Results
Characteristics of study population
History of diabetes, mental disorders as well as antidepressant and antipsychotic use were more common among AD cases. (Table 1 ). There were no major differences in socioeconomic position.
Use of any BZDR was more common among cases (40.2%) than controls (37.0%) due to more common use of BZDs (Table 2 ). Cases were also more likely to have used both BZDs and Z drugs, or short-/medium-and long-acting BZDRs.
Total cumulative consumption of BZDRs and BZDs in DDDs during the follow-up was higher in cases, and duration of use was longer than in controls (Table S3) . Similar, although smaller differences were observed with Z drug consumption. Cases also used both short-/medium-acting and long-acting BZDRs for longer periods. There were no significant differences in average BZDR doses (DDD/day). Assessment of BZDR use duration according to dose categories showed that highest doses were used shorter time and total consumption of BZDRs was smaller in the highest dose group (Table S4) .
Average time for exposure assessment (the 5-year time lag not included in the exposure assessment time) was 8.7 years (SD 2.0). The exposure assessment time ranged from 5.0 years to 11.9 years.
Association between any BZDR use and AD Any BZDR use was associated with an increased risk of AD (OR 1.19, 95% CI 1.17-1.21) compared with no use ( Table 2 ). The association was attenuated after adjustment for comorbidities, socioeconomic position and use of other psychotropics (OR 1.06, 95% CI 1.04-1.08) The attributable proportion among the exposed was 0.057. Similar associations were observed with the use of BZD or Z drug alone. The same pattern was observed with short-/medium-and long-acting BZDRs.
Average BZDR dose and the risk of AD
In average dose analysis among BZDR users, unadjusted ORs were slightly higher in persons with lower average dose compared to higher doses ( Table 3 ). The same was evident among BZD users. Z drug use was not associated with AD in low dose group, and the highest risk was observed in the medium dose group. In general, the differences were small and the 95% CIs were overlapping.
Adjustments for comorbidities, socioeconomic position and other psychotropics slightly lowered ORs and removed the associations in high-dose groups among BZDR users and BZD users but did not change previously mentioned order of risks.
Duration of BZDR use and AD risk
The risks in all drug categories were the highest in the two longest duration of use groups (1-5 years AD, Alzheimer's disease; BZDR, Benzodiazepine and related drug; BZD, Benzodiazepine. †Adjusted for any mental disorder, substance abuse, asthma/COPD, cardiovascular disease (arrhythmia, hypertension, coronary disease or heart failure), diabetes and socioeconomic position. ‡Adjusted for antidepressant use, antipsychotic use, any mental disorder, substance abuse, asthma/COPD, cardiovascular disease (arrhythmia, hypertension, coronary disease or heart failure), diabetes and socioeconomic position. and >5 years), and the risks slightly lowered in shorter use compared to nonusers of each drugs (Table 4 ). In the fully adjusted model, no risks were observed in the shortest use (1 day-1 month) and the risks increased until the second longest (1-5 years) duration of use group. No significant differences in risks between BZDs and Z drugs, or short-/medium-and long-acting BZDRs were observed.
Cumulative BZDR consumption and risk of AD
In unadjusted analyses, a dose-response relationship was evident in the DDD analyses and less clear in the equivalent dose analyses where the ORs for the highest category were similar to the lowest category for BZDRs and Z drugs (Table 5 ).
In the fully adjusted model, the differences between the highest and lowest category disappeared and the highest ORs were seen in the second tertiles of each drug category. Similar results were observed with equivalent doses.
Discussion
Our study showed that the past use of BZDRs was associated with modestly increased risk of AD (adjusted OR 1.06, 95% CI 1.04-1.08). The attributable proportion among the exposed was 0.057, meaning that assuming there was no uncontrolled bias or confounding, 5.7% of AD cases occurring among BZDR users were attributable to exposure. This is worrying because BZDRs are commonly used among old persons (1-5), and despite recommendations (7), the use is often long term (8) . This is the first study on this topic that also included BZD combination products. Adjustment for other psychotropics removed the dose-response relationship by attenuating the ORs in the highest cumulative consumption category.
Comparison with other studies
All drug categories (BZDRs, BZDs, Z drugs, short-/medium-acting and long-acting BZDRs) were associated with higher risk of AD. No major AD, Alzheimer's disease; BZDR, Benzodiazepine and related drug; BZD, Benzodiazepine. †Adjusted for any mental disorder, substance abuse, asthma/COPD, cardiovascular disease (arrhythmia, hypertension, coronary disease or heart failure), diabetes and socioeconomic position. ‡Adjusted for antidepressant use, antipsychotic use, any mental disorder, substance abuse, asthma/COPD, cardiovascular disease (arrhythmia, hypertension, coronary disease or heart failure), diabetes and socioeconomic position.
differences between these categories were observed. The overall risk of past BZDR use we found was smaller than in most previous studies (18, 21, 22) . One previous study found no association (20) . It was also only previous study that investigated Z drugs separately and did not find association between Z drugs or BZDs and AD. Some (18, 19, 21) but not all (20) studies have found higher risk of dementia for long-acting BZDR use compared to short-/medium-acting use. Classifications into short-/medium-acting and long-acting BZDRs varied in previous studies, and therefore, their results are not directly compared to ours. Lower (≥0 to <0.5 DDD/day) average doses of BZDRs increased the risk more than the higher doses (≥0.5 DDD/day). One explanation for this is that highest doses were used shorter time and total consumption of BZDRs was smaller in the highest dose group. In addition, high and low doses might have been used for different indications. Our result is contrary to previous study (18) where average dose -dependent association was found. However, the differences between average dose categories in our results were small. Similar to a previous study (21) , a dose-response relationship between cumulative BZDR consumption and AD was observed when other psychotropics were not taken into account. In our study, adjustment for psychotropics removed the dose-response relationship, suggesting that the association was at least partially explained by more frequent use of other psychotropics among high-dose users. This result is in line with one previous study (17) , which found risk for dementia with two lowest cumulative consumption categories but not with the highest consumption category. In that study, an increased risk for dementia was observed with 1-and 2-year lag time, but none with a 5-year lag time which is contrary to our findings. Another study with 2-year lag time also concluded with null results (20) . It might be that these null results are due to lack of power as both these studies had considerably smaller study samples, low number of AD cases and persons in subcategories. Gray et al. (34) and Ashton Manual (35) . †Adjusted for any mental disorder, substance abuse, asthma/COPD, cardiovascular disease (arrhythmia, hypertension, coronary disease or heart failure), diabetes and socioeconomic position. ‡Adjusted for antidepressant use, antipsychotic use, any mental disorder, substance abuse, asthma/COPD, cardiovascular disease (arrhythmia, hypertension, coronary disease or heart failure), diabetes and socioeconomic position.
Strengths and weaknesses of the study
Our study is a nationwide nested case-control study of all community-dwelling AD cases who received a clinically verified AD diagnosis in 2005-2011. The diagnoses were confirmed according to a standardized protocol, and the positive predictive value of diagnoses is high (PPV 97.1%) (36) . To our knowledge, our study is the largest one in this topic and this enabled us to perform more detailed analyses according to the duration, dose and type of BZDRs. In addition, due to the long exposure assessment, we were able to use a 5-year time lag between exposure and outcome, which is longer than in main analyses of most of the previous studies (17) (18) (19) (20) and accounts at least partially for the reverse causality. The 5-year time lag is justified by our previous studies in the same population, showing that a steep increase in the use of antidepressants (37) and antipsychotics (38) occurs in this time window. A further strength is the exposure ascertainment. We used data on purchased prescriptions, which were modelled to actual use periods with a validated PRE2DUP modelling method (32) . This enabled us to assess duration of use and dose (intensity of use) issues properly, which offer additional information on the associations between different drug use patterns. Further, including combination BZDs as exposures reduces indication bias as combinations are indicated for a larger variety of symptoms (such as gastrointestinal cramps, dizziness and muscle tension) than traditional BZDs. This also reduces the possibility of protopathic bias.
Our study is limited in the sense that only reimbursed BZDR purchases were included. It is likely that nonreimbursed small size packages were equally often purchased by cases and controls. This would dilute our estimates by increasing the confidence intervals, but not cause systematic bias. Thus, our results may be an underestimation. In addition, Prescription Register does not include information on drug use in hospital. This might have caused some misclassification of exposure. However, as we restricted the analyses to time preceding AD diagnosis by at least 5 years, it is likely that the amount of possibly misclassified exposure time was similar between cases and controls.
In conclusion, BZDR use in general was associated with modestly increased AD risk, with no major differences between BZDR subcategories (i.e. BZD, Z drug, short-/medium-acting or longacting). Due to frequent use of BZDRs among older people, even small increases in absolute risk may be important on a population level. A doseresponse relationship between BZDR use and AD was observed, but adjustment for other psychotropics removed this relationship suggesting that the association was at least partially explained by more frequent use of antidepressants and/or antipsychotics, or reasons for concomitant use of these medications. Even though association between BZDR use and AD was modest in this study, BZDRs should be avoided if possible and threshold for prescribing should be high enough due to overall adverse effect profile of the BZDRs.
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